Endocrine Tumor Research Foundation Inc
| Fiscal year | Revenue | Expenses | Net | Reserve mo. | Staff % |
|---|---|---|---|---|---|
| 2011 | 18,702 | 27,743 | −9,041 | 7.7 | 0% |
| 2012 | 22,318 | 1,929 | 20,389 | 238.3 | 0% |
| 2013 | 18,556 | 1,977 | 16,579 | 333.1 | 0% |
| 2014 | 13,472 | 5,673 | 7,799 | 132.6 | 0% |
| 2015 | 42,704 | 363 | 42,341 | 3471.8 | 0% |
| 2016 | 22,176 | 226 | 21,950 | 6741.8 | 0% |
| 2017 | 11,400 | 11,520 | −120 | 132.1 | 0% |
| 2018 | 31,086 | 11,889 | 19,197 | 147.4 | 0% |
| 2019 | 14,839 | 11,955 | 2,884 | 149.5 | 0% |
| 2020 | 13,606 | 5,434 | 8,172 | 346.9 | 0% |
| 2021 | 196,553 | 38,326 | 158,227 | 98.7 | 0% |
| 2022 | 162,114 | 26,212 | 135,902 | 206.6 | 0% |
| 2023 | 4,546 | 24,419 | −19,873 | 212.0 | 0% |
In its most recent public year (2023), this organization spent $19,873 more than it brought in. Its reserves stood at about 212 months of spending, up from 7.7 in 2011. Staff pay was 0% of spending.
Reserve months = net assets ÷ average monthly spending; net assets count everything the organization owns beyond its debts — buildings and donor-restricted funds included, not just cash. Staff pay = salaries, wages, and officer compensation; it excludes benefits and payroll taxes. The IRS releases this data years after the fact — this organization's newest public year is 2023. Years refer to the calendar year in which the organization's fiscal year ended. Short-form filers do not publicly report donor-restricted balances or staffing costs. Source filings
Endocrine Tumor Research Foundation Inc's IRS filings as a feed — one entry per filing year, through 2023. Add the address to any feed reader; in Slack, send /feed subscribe with it (pasting the link alone won't subscribe). How this feed works